chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I tested positive at home. I was asymptomatic. I isolated on 12/1/2021. I started having blurry vison in my left eye. It was red, tearing, and crusty. I had an intermittent cough. On 12/2/2021 I went to an urgent care and had another another COVID test did. It was confirmed that I did have COVID. I ran a low grade temperature of about 99 degrees. I had more significant fatigue, a stuffy nose, a  headache, and body aches. My eye seemed better but still red and I had an intermittent cough still. On 12/3/2021 I was feelin better, but the low grade fever came back. I was very tired and had a stuffy nose. On 12/4/2021 my fever went away. I just had a mild headache, some congestion, and some fatigue. On 12/5/2021 I had a normal temperature, joint pain, and still felt  fatigued. I started having a little bit of occasional diarrhea. On 12/6/2021 I was asymptomatic but still had  occasional diarrhea and my nose felt a little clogged but the congestion is mostly gone. I checked my O2 levels that night when I tested positive for COVID and it was at 96% and has been 97% since then. I didn't have any respiratory problems just a stuffy nose.
For 2-3 weeks, episodes of L ear numbness, top of ear, lasting for 10-15 seconds multiple times during the day and then goes away. But comes back, sometimes some electric feeling.
I developed small white circles around the site of my shot that are still there today. After my 2nd dose I had passed a few smaller stones and had a follow-up appointment in November of 2021 (after my 3rd dose) and a cat scan picked up two large kidney stones that were too big to pass naturally. I had a surgery in Jan 2022 to remove the stones. The surgery itself created a lot of new issues. I have since recovered from the kidney stones.
Pt recvd MMR/TB skin test & became nervous during TB skin test; Told to wait 20 min, while waiting became pale, diaphoretic; Layed in floor given 02; BP 90/60, 92/60, 98/60, P80;
Soreness, turned to localized swelling, warm to touch and itchy. Area turned larger and more painful (6x4" area) itchiness increased. Patient reports icing. 6 days after event area still swollen, warm to touch, and itching. Recommended anti-inflammatories, continuing ice packs and hydrocortisone.
Hard lump on injection site. It?s itchy. Flatulence began on day of injection and has continued for 9 days.
1. There were NO REPORTED ADVERSE EVENT.  2. Vaccine was administered at 8 days past the UPDATED EXPIRY of 08/23/21 though still within vaccine PACKAGE EXPIRY date of 08/31/21.  3. Only filing as a VACCINE ADMINISTRATION ERROR report
I did not have an adverse reaction to the vaccine. I was exposed to COVID-19 while on vacation. I tested positive for COVID-19 on 03/25/2023. I contacted my doctor in an email and I got a prescription for Paxlovid. I tolerated the medication without any complications. As of today, I continue to feel very tired.
Headache almost every day since the vaccine Heartburn almost every day since the vaccine Bowel issues including constipation Fluttering in chest periodically Periods of overheating and lightheadedness None of these symptoms are normal for me
Information has been received from a LPN concerning a 41 year old white male volunteer firefighter with no known allergies and no known medical conditions who on 12/02/2002 at 19:00 was vaccinated IM in the deltoid with a first dose of pneumococcal vaccine 23 polyvalent (Lot # 643251/0445M).  On 12/02/2002 at 19:00 concomitant therapy included an IM dose in the "opposite deltoid" of influenza vaccine (FLUZONE) (Batch # U0925AA). Both doses were "given with a 25 guage 1" needle".  Other concomitant medications were propranolol HCl (INDERAL), doxepin HCl and alprazolam (XANAX).  There was no illness at the time of vaccination and no symptoms following prior vaccinations with the patient or his siblins.  It was noted that 2 hours after the vaccine was given, he spent 20 hours at a fire scene and was engaged at times in "heavy physical labor".  On 12/03/2002 at 21:00 the patient developed pain, redness, swelling, "induration from elbow to shouler" and did not require medical care as result of this.  It was also noted that the nurse had suspected the "activity played a major role in their reactions".  The patient recovered on 12/09/2002 after 1 week.  The nurse also reported on 9 other patients that were vaccinated with a first dose of pneumococcal vaccine 23 polyvalent (Lot # 643251/0445M) and developed induration (WAES #'s: 0212USA01192, 0212USA01193, 0212USA00729, 0212USA00825, 0304USA02075, 0304USA02076, 0304USA02077, 0304USA02078, 0304USA02079).  No further information is expected.
The patient developed a rash on her L lower arm 1 day following her second dose of the Pfizer covid-19 vaccine. Supportive treatment was provided. The rash was improving on 2/10/2021 when we spoke. We are following her closely. Her symptom is not yet resolved.
Diarrhea, sore throat, muscle aches, fatigue, chills, swollen, painful glands on neck and under arms.
Diarrhea; Body aches; Fever of 100.2 F; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), MYALGIA (Body aches), PYREXIA (Fever of 100.2 F) and FATIGUE (Tiredness) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced DIARRHOEA (Diarrhea), MYALGIA (Body aches), PYREXIA (Fever of 100.2 F) and FATIGUE (Tiredness). On 09-Mar-2021, DIARRHOEA (Diarrhea) had resolved. At the time of the report, MYALGIA (Body aches), PYREXIA (Fever of 100.2 F) and FATIGUE (Tiredness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   This case was linked to MOD-2021-039342 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Follow up received no new significant information available.; Sender's Comments:  MOD-2021-039342:cross linked, daughter case
5/22/14 late AM received PNEUMOVAX vaccine. Was starting a call at time. By evening injection site was very sore and lasted until Sat night. Friday evening started rash - red, hot about 5 inches long by 3 inches wide - lasted 1-2 days. Remained afebrile. 5/27 - arm better now. Has heavy cold - nasal congestion.
Information has been received from a registered nurse referring to a female girl patient of unknown age. The patient's medical history, concurrent condition and other concomitant medication were not reported. On 03-APR-2018, the patient was vaccinated with improperly stored VARIVAX (dose, route unknown, lot # N015475 with expiration date 18-MAY-2019)  for prophylaxis. The sterile diluent (manufacturer unknown) (unknown lot number and expiration date) used for reconstitution was properly stored. The vaccine was exposed to temperature excursion of -14 degree Celsius to -10 degree Celsius for a time frame of 2 hours. There were no previous temperature excursions.  Data logger was involved. No product quality complaint (PQC) was involved in this case. No adverse effects reported. This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1805USA011818: US-009507513-1805USA011820: US-009507513-1805USA011821: US-009507513-1805USA011822: US-009507513-1710USA004084:
Dizziness; This case was reported by a consumer via interactive digital media and described the occurrence of dizziness in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced dizziness. On an unknown date, the outcome of the dizziness was unknown.   It was unknown if the reporter considered the dizziness to be related to Shingrix.     Additional Information: GSK Receipt Date: 24-JUL-2022 Reporter's Comments: This case was reported by the consumer via interactive digital media. The patient had dizziness after Shingrix. The follow up not possible as contact details were not provided.
Information has been received from a physician concerning her niece, a 16 year old female who on unspecified dates was vaccinated with the first and second doses of GARDASIL, 0.5 ml.  In February 2008, the patient experienced cellulitis type skin condition.  She was seen by a dermatologist and she was hospitalized a few times with diagnosis of Morphea, an autoimmune disease.  In March 2008, the patient was vaccinated with the third dose of GARDASIL, 0.5 ml, with no additional reaction or exacerbation of symptoms noted.  At the time of report, the patient had not recovered.  No additional information at this time.  Additional information has been requested.
Severe seizure (grand mal) lasting over 3 hours. Life flighted and hospitalized for 5 days. Results-permanent brain damage to the left hippocampus.Since his vaccination, he has epilepsy, autism, sensory processing disorder and brain damage. He will be having brain surgery on 3/15/2010.
Stopped bleeding; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 50 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 04Oct2021 17:00 (Lot number: FF3590) at the age of 50 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (lot number= EC3184, administration date=13Sep2021,, administration time=04:45 PM  , dose number=1, vaccine location=Left arm), administration date: 13Sep2021, when the patient was 50 years old, for Covid-19 immunization, reaction(s): "Started menstrual bleeding". The following information was reported: MENSTRUAL DISORDER (non-serious) with onset 2021, outcome "recovered" (2021), described as "Stopped bleeding". Therapeutic measures were not taken as a result of menstrual disorder.  No follow-up attempts are possible. No further information is expected.
Information has been received from a physician concerning a 17 month old male who on 06-NOV-2003 was vaccinated with a dose of MMR II (lot# not reported). Subsequently the patient developed unilateral (left) parotitis. Unspecified medical attention was sough. Additional information has been requested.
PATIENT RECEIVED A COVID DOSE AFTER BEYOND USE DATE OF 12/17/2022 FOR DOSE #3 PATIENT RECEIVED A COVID DOSE AFTER BEYOND USE DATE OF 03/02/2023 FOR DOSE #2
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient. A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PARAESTHESIA (non-serious), outcome "not recovered", described as "pins and needles from my shoulder 2 finger tip". The lot number for bnt162b2 was not provided and will be requested during follow up.
Arm red, swollen, and tender.  Treated with ice and heat for several days.
ring of red; redness measured 2 inches wide and 3 1/2 inches long; scab; This spontaneous case was reported by a consumer and describes the occurrence of SCAB (scab), ERYTHEMA (ring of red) and VACCINATION SITE ERYTHEMA (redness measured 2 inches wide and 3 1/2 inches long) in a 91-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 00A4212) for COVID-19 vaccination.     The patient's past medical history included Tuberculosis (being interned for 4 1/2 years.), Pregnancy (Patient had four pregnancies with no issues) and Venous ligation. Concomitant products included CETIRIZINE HYDROCHLORIDE, METOPROLOL, RALOXIFENE, APIXABAN (ELIQUIS) and ATORVASTATIN CALCIUM (STATIN [ATORVASTATIN CALCIUM]) for an unknown indication.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced SCAB (scab). On 04-Mar-2021, the patient experienced ERYTHEMA (ring of red) and VACCINATION SITE ERYTHEMA (redness measured 2 inches wide and 3 1/2 inches long). At the time of the report, SCAB (scab), ERYTHEMA (ring of red) and VACCINATION SITE ERYTHEMA (redness measured 2 inches wide and 3 1/2 inches long) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient had her first administration of the Moderna COVID-19 Vaccine in her left non-dominant arm on 25Feb2021 without issue. While in the shower, sometime after receiving the vaccine, she pulled a scab from the injection site and the next day, on 04Mar21 or 05Mar21 she noticed a ring of red, reddish, not a rash, not itchy, ring around injection site. The redness measured 2 inches wide and 3 1/2 inches long. She reports that two days ago, on 06Mar2021, she applied cortisone but the red area hasn't gotten bigger and hasn't gotten smaller.  She plans on taking an allergy pill sometime today as she usually takes it when she has a reaction.
Pt. reported extreme pain and difficulty range of motion less than 2 weeks after being vaccinated.
Patient is 20 weeks pregnant, vaccine was given at 10:30 am and itching and redness began in 5 minutes. Patient was given 10ml(25mg) of generic Benadryl at 10:37am. Patient stated no trouble breathing during the entire adverse reaction. Blood Pressure was 135/84 at 10:42, 130/84 at 10:52, 145/91 at 11am and 136/87 at 11:05(opposite arm this time). Patient's spouse picked her up at 11:15am to drive her to nursing school for exam. Spoke to Layla at 11:25 at the OBGYN office.  She advised to check her BP several more times throughout the day. She also advised for patient to take another dose of Benadryl at normal sched time.    I called patient at 11:49 to check on her and she stated the itching has subsided more and she would take her BP as soon as arriving at campus.    Patient spoke to the doctor's office and they advised her to continue to check her BP and go to nearest emergency room if she had difficultly breathing.    Layla was my contact the Longstreet Clinic, a registered nurse
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a male patient who received SHINGRIX for prophylaxis. On 6th November 2018, the patient received the 2nd dose of SHINGRIX. On 7th November 2018, 1 days after receiving SHINGRIX, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient reported that he got his SHINGRIX shot on left arm. The patient had arm soreness at the injection site on the day of reporting and wanted to know if he could lift weights. The patient was referred to his physician. The patient did not consent to follow-up. The patient declined to provide demographics or details. The patient did not know the lot number.
Pt says she had a lot of pain immediately after her flu shot administration... she has had pain for last 5 days, to the point where she cannot lay on that arm at night.
Itchiness in legs and back with no hives; itchiness in left arm at injection site; ear started to itch; nose hairs stood up; Breathing got a little shallow; back of neck had raised skin; This spontaneous case was reported by a consumer and describes the occurrence of EAR DISCOMFORT (ear started to itch), NASAL DISCOMFORT (nose hairs stood up), HYPOPNOEA (Breathing got a little shallow), SKIN INDURATION (back of neck had raised skin) and PRURITUS (Itchiness in legs and back with no hives) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No relevant medical history was reported.  Concomitant products included TRAZODONE, HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HCTZ), AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL), MELATONIN and LORAZEPAM for an unknown indication.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021, the patient experienced EAR DISCOMFORT (ear started to itch) and NASAL DISCOMFORT (nose hairs stood up). 24-Apr-2021, the patient experienced HYPOPNOEA (Breathing got a little shallow), SKIN INDURATION (back of neck had raised skin) and VACCINATION SITE PRURITUS (itchiness in left arm at injection site). On an unknown date, the patient experienced PRURITUS (Itchiness in legs and back with no hives). At the time of the report, EAR DISCOMFORT (ear started to itch), NASAL DISCOMFORT (nose hairs stood up), HYPOPNOEA (Breathing got a little shallow), SKIN INDURATION (back of neck had raised skin), PRURITUS (Itchiness in legs and back with no hives) and VACCINATION SITE PRURITUS (itchiness in left arm at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment was given for symptoms.
Patient went to  ED on 3/21/2021, due to reaction from vaccine. C/o  chills, headache, generalized rash,  body aches and hives. At hospital when examined by physician patient observed with anterior chest and back with urticarial rash that is pleuritic, rash also evident in the left arm bilateral hands and soles of feet all of which are pruritic .
DX altered mental status, Pneumonia due to COVID; 79y.o. female who presents with SOB, fatigue and COVID concerns. In the emergency department, she was noted to be hypoxic with SpO2 within the 89% range.  She was placed on 2 liters of O2 via nasal She recalls her family coming over to make her food and then home what she remembers, she found herself on the back of an ambulance. cannula with appropriate response of her SpO2 to the 92 to 94 range.  She was given IV Decadron and remdesivir and lovenox. Discharged to home.
Vesicular rash dx as chickenpox. Onset 10/27/05 symptomatic care.
pt recv vax 25MAR98 & 30MAR98 AM mom noticed fifty cent size rash like area;referral to take child to MD 2AM 30MAR98;
Pt. developed redness and warmth at injection site. Pt visited Doctor who prescribed antibiotic as precaution. Pt notified Pharmacist when picking up Rx.
Mother reported childs left arm at injection site was red, and hot.  Child was brought to office for the nurse to see him, the injections site was red, raised and warm to the touch.  Pt denies discomfort. Family will call if no improvment.
Patient complained of increased pain in right arm. Noted large area of redness/swelling/warmth to right upper extremity. Patient's skin was taut and area was swollen and painful. Patient's parent administered MOTRIN dosed by weight for pain and discomfort/swelling. Ice also applied to area. Patient also attended dance class per her normal schedule. Patient stated that twice during practice she suddenly became dizzy, blacked out, and fell to the floor. She does not know if she lost consciousness. Her friends around her had to help her up. Mom was instructed to draw a line on the skin to make sure that the redness began to subside and not spread. 36 hours after vaccine and treatment to area as discussed above, patient reported less pain and redness had not spread beyond the line but had not subsided. Right arm continues to be swollen and red area "feels hard" per patient's mom.
Received Tdap 9/3/19 - developed pain, swelling, within several hours increased pain & swelling 9/4/19. Seen in ED 9/6/19 - treated with Tylenol, ibuprofren, ice.
Mom noted at site of shot red raised, vesicles, today on day of appt has noted approximately 10 vesicles or less different areas on body, thigh, back, chest, neck and arm, no fevers.
No additional AE reported; Patient was administered expired PROQUAD; This spontaneous report was received from a physician via a company representative and refers to a patient of unknown age and gender. The patient's medical history, concomitant medications, concurrent conditions and drug allergies were not reported.  On 19-APR-2022, the patient was vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live, recombinant human albumin (rHA) (PROQUAD) lot # T034826 was found to be valid, expiration date 11-APR-2022 (expired product administered) (dose, route of administration and injection site were not reported) for prophylaxis. No additional adverse events were reported. The reporter confirmed, that it was no temperature reported for the affected vaccine.
Arm pain, body aches, chills, fever, fatigue, headache, muscle pain, joint pain.
This spontaneous report was received from a register nurse concerning a 1 year old patient of an unknown gender. Medical history and concurrent conditions were not reported. On 05-MAR-2014, the patient was vaccinated with M-M-R II (route was not reported) lot # J006954, expiration date 07-JUN-2015. Co-suspect and concomitant therapies were not reported. The register nurse reported that M-M-R II went through a unsupported temperature excursion; however 10 doses of M-M-R II were overlooked because thet were stored in the fridge. These doses were administered to 10 patients. This case pertain to one of them who had not received repeat dose date. This case is linked to 1404USA001099, 1404USA001100, 1404USA001101, 1404USA001102, 1404USA014293, 1404USA014294, 1404USA014295, 1404USA014296, 1404USA014297, 1404USA014298, 1404USA014299, 1404USA01430 and 1403USA010165. Additional information has been requested.
Patient developed croup 2 days after Prevnar given on 3/30/06 and again 2 days after 10/4/06 dose.
Information has been received from a healthcare worker referring to unspecified number of patients of unknown age and gender. On an unknown dates the patients were vaccinated with M-M-R II (lot#, expiration date, dose and route were unknown). On an unknown dates the patients experienced injection site pain. The reporter did not mention a specific patient or a specific incident, but just made a general comment. The outcome of injection site pain was unknown. Additional information is not expected as the reporter declined to provide any additional information.
Received Hib in (L) deltoid 6/25. Increasing redness the following day, then developed large blisters surrounding the injection site later on 6/26/ and 6/27.
Patient not sure if vaccination was on 3/25 or 3/26. Patient received the vaccine around mid-day; adverse events started 2 or 3 hours later. Per patient, around vaccine injection area turned bright red (6x6 inch), it was itchy and there were little bumps (about 7) in area. Patient called pharmacy to report adverse events and told problems should resolve within a couple of days. Also called doctor and was told not to take the 2nd shot. It took about 10-14 days to resolve completely; it was the worse the fist 24 hours and stayed in that peak for 5-6 days and then lessened. Patient did not take any medications just avoided itching.
Broke out with red patches and small white welts on upper torso and itching; within 5 mins of receiving immunizations.  BENADRYL was given (1 1/2 ml) PO and advised to go to ER for additional evaluation.
10 days  and about 10 hours following my second vaccine, I experienced significant headache, body aches and  fever (that was initially, 100.8 and peaked the following night at 101.6 F.).  This morning (about 30 hours from the first appearance of symptoms, all symptoms had abated).
very mild flu-like symptoms-employee reported feeling hot for 2 days after injection Narrative: